Future Price to Earnings: Orgenesis Corporation (ORGS)

Orgenesis Inc. is optimizing its IT architecture and biosafety to reduce costs, which is supported by the company's forward P/E ratio. The value 0.00 reflects the current level of this metric as management adapts services to meet market demands. High scalability is achieved by providing software to clinics, allowing the business to grow without constructing its own plants.

ORGS - orgenesis.com Forward Price to Earnings Multiple over the range 07/04/2022 - 10/26/2024

Orgenesis Corporation (ORGS) - metric breakdowns and financial figures

- stock value and consensus price forecast:

Price Chart Orgenesis|ORGS - Average Forecast Price

- company stock exchange capitalization indicators:

Market Value Orgenesis Inc|ORGS - Value Adjusted for Debt and Cash

- balance sheet equity data:

Book Value per Share Orgenesis|ORGS - Book Value of Business|Market Capitalization to Book Value Ratio orgenesis.com|ORGS - Company Assets

- debt burden and liquidity indicators:

- earnings and market ratios statistics:

ORGS - Net Financial Result|Future Profit Orgenesis Inc.|ORGS - Company Value to Net Income|Forward P/E Multiple Orgenesis Corp|ORGS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Orgenesis Inc|ORGS - Operating profit before amortization|Net earnings per share (EPS TTM) Orgenesis|ORGS - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months orgenesis.com|ORGS - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Orgenesis Inc.

Analysis of all company metrics:ORGS Orgenesis

Signature product of Orgenesis Corporation

The forward P/E reflects the ratio of the current market share price to expected net income, allowing for an assessment of the optimism priced in regarding future cash flows. By analyzing the expected price-to-earnings multiple of Orgenesis Inc. (ORGS), an investor can compare the growth rates of the Orgenesis CDMO platform within the gene therapy segment against market expectations to determine the fairness of the business valuation amid the expansion of the RNA innovation market.

Main competitors